ArticleCancer immunology, immunotherapy : CII2026

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Veronica Mollica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.